Cargando…

Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease

BACKGROUND: Inflammatory bowel disease (IBD) is a chronic nonspecific disease with unknown etiology. Currently, the anti-inflammatory therapeutic approaches have achieved a certain extent of effects in terms of inflammation alleviation. Still, the final pathological outcome of intestinal fibrosis ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yameng, Cheng, Kai, Yang, Mei, Deng, Zhichao, Ma, Yana, Yan, Xiangji, Zhang, Yuanyuan, Jia, Zhenzhen, Wang, Jun, Tu, Kangsheng, Liang, Jie, Zhang, Mingzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854161/
https://www.ncbi.nlm.nih.gov/pubmed/36658555
http://dx.doi.org/10.1186/s12951-023-01770-0
_version_ 1784873057695825920
author Cao, Yameng
Cheng, Kai
Yang, Mei
Deng, Zhichao
Ma, Yana
Yan, Xiangji
Zhang, Yuanyuan
Jia, Zhenzhen
Wang, Jun
Tu, Kangsheng
Liang, Jie
Zhang, Mingzhen
author_facet Cao, Yameng
Cheng, Kai
Yang, Mei
Deng, Zhichao
Ma, Yana
Yan, Xiangji
Zhang, Yuanyuan
Jia, Zhenzhen
Wang, Jun
Tu, Kangsheng
Liang, Jie
Zhang, Mingzhen
author_sort Cao, Yameng
collection PubMed
description BACKGROUND: Inflammatory bowel disease (IBD) is a chronic nonspecific disease with unknown etiology. Currently, the anti-inflammatory therapeutic approaches have achieved a certain extent of effects in terms of inflammation alleviation. Still, the final pathological outcome of intestinal fibrosis has not been effectively improved yet. RESULTS: In this study, dextran-coated cerium oxide (D-CeO(2)) nanozyme with superoxide dismutase (SOD) and catalase (CAT) activities was synthesized by chemical precipitation. Our results showed that D-CeO(2) could efficiently scavenge reactive oxide species (ROS) as well as downregulate the pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and iNOS) to protect cells from H(2)O(2)-induced oxidative damage. Moreover, D-CeO(2) could suppress the expression of fibrosis-related gene levels, such as α-SMA, and Collagen 1/3, demonstrating the anti-fibrotic effect. In both TBNS- and DSS-induced colitis models, oral administration of D-CeO(2) in chitosan/alginate hydrogel alleviated intestinal inflammation, reduced colonic damage by scavenging ROS, and decreased inflammatory factor levels. Notably, our findings also suggested that D-CeO(2) reduced fibrosis-related cytokine levels, predicting a contribution to alleviating colonic fibrosis. Meanwhile, D-CeO(2) could also be employed as a CT contrast agent for noninvasive gastrointestinal tract (GIT) imaging. CONCLUSION: We introduced cerium oxide nanozyme as a novel therapeutic approach with computed tomography (CT)-guided anti-inflammatory and anti-fibrotic therapy for the management of IBD. Collectively, without appreciable systemic toxicity, D-CeO(2) held the promise of integrated applications for diagnosis and therapy, pioneering the exploration of nanozymes with ROS scavenging capacity in the anti-fibrotic treatment of IBD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01770-0.
format Online
Article
Text
id pubmed-9854161
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98541612023-01-21 Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease Cao, Yameng Cheng, Kai Yang, Mei Deng, Zhichao Ma, Yana Yan, Xiangji Zhang, Yuanyuan Jia, Zhenzhen Wang, Jun Tu, Kangsheng Liang, Jie Zhang, Mingzhen J Nanobiotechnology Research BACKGROUND: Inflammatory bowel disease (IBD) is a chronic nonspecific disease with unknown etiology. Currently, the anti-inflammatory therapeutic approaches have achieved a certain extent of effects in terms of inflammation alleviation. Still, the final pathological outcome of intestinal fibrosis has not been effectively improved yet. RESULTS: In this study, dextran-coated cerium oxide (D-CeO(2)) nanozyme with superoxide dismutase (SOD) and catalase (CAT) activities was synthesized by chemical precipitation. Our results showed that D-CeO(2) could efficiently scavenge reactive oxide species (ROS) as well as downregulate the pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and iNOS) to protect cells from H(2)O(2)-induced oxidative damage. Moreover, D-CeO(2) could suppress the expression of fibrosis-related gene levels, such as α-SMA, and Collagen 1/3, demonstrating the anti-fibrotic effect. In both TBNS- and DSS-induced colitis models, oral administration of D-CeO(2) in chitosan/alginate hydrogel alleviated intestinal inflammation, reduced colonic damage by scavenging ROS, and decreased inflammatory factor levels. Notably, our findings also suggested that D-CeO(2) reduced fibrosis-related cytokine levels, predicting a contribution to alleviating colonic fibrosis. Meanwhile, D-CeO(2) could also be employed as a CT contrast agent for noninvasive gastrointestinal tract (GIT) imaging. CONCLUSION: We introduced cerium oxide nanozyme as a novel therapeutic approach with computed tomography (CT)-guided anti-inflammatory and anti-fibrotic therapy for the management of IBD. Collectively, without appreciable systemic toxicity, D-CeO(2) held the promise of integrated applications for diagnosis and therapy, pioneering the exploration of nanozymes with ROS scavenging capacity in the anti-fibrotic treatment of IBD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01770-0. BioMed Central 2023-01-19 /pmc/articles/PMC9854161/ /pubmed/36658555 http://dx.doi.org/10.1186/s12951-023-01770-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cao, Yameng
Cheng, Kai
Yang, Mei
Deng, Zhichao
Ma, Yana
Yan, Xiangji
Zhang, Yuanyuan
Jia, Zhenzhen
Wang, Jun
Tu, Kangsheng
Liang, Jie
Zhang, Mingzhen
Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease
title Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease
title_full Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease
title_fullStr Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease
title_full_unstemmed Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease
title_short Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease
title_sort orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854161/
https://www.ncbi.nlm.nih.gov/pubmed/36658555
http://dx.doi.org/10.1186/s12951-023-01770-0
work_keys_str_mv AT caoyameng orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT chengkai orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT yangmei orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT dengzhichao orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT mayana orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT yanxiangji orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT zhangyuanyuan orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT jiazhenzhen orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT wangjun orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT tukangsheng orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT liangjie orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease
AT zhangmingzhen orallyadministrationofceriumoxidenanozymeforcomputedtomographyimagingandantiinflammatoryantifibrotictherapyofinflammatoryboweldisease